(Q37039628)

17 August 2017

1 reference

title

Exploiting signal transduction pathways in acute myelogenous leukemia (English)

1 reference

17 August 2017

1 reference

Alexander E Perl

1

1 reference

PubMed ID

18097642

17 August 2017

Martin Carroll

series ordinal

2

1 reference

17 August 2017

1 August 2007

1 reference

Current Treatment Options in Oncology

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

4

1 reference

17 August 2017

265-276

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-007-0043-z

17 August 2017

0 references

cites work

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

1 reference

12 December 2020

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

1 reference

12 December 2020

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

1 reference

12 December 2020

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

12 December 2020

Expression of normal and mutant ras proteins in human acute leukemia

1 reference

12 December 2020

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

12 December 2020

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

1 reference

12 December 2020

A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

1 reference

12 December 2020

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

12 December 2020

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

12 December 2020

Evidence of increased angiogenesis in patients with acute myeloid leukemia

1 reference

12 December 2020

Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia

1 reference

12 December 2020

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Internal tandem duplication of the flt3 gene found in acute myeloid leukemia

1 reference

12 December 2020

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

1 reference

12 December 2020

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

12 December 2020

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

12 December 2020

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

12 December 2020

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

12 December 2020

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).

1 reference

12 December 2020

The roles of FLT3 in hematopoiesis and leukemia

1 reference

12 December 2020

Survival of acute myeloid leukemia cells requires PI3 kinase activation

1 reference

12 December 2020

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

12 December 2020

mTOR regulates cell survival after etoposide treatment in primary AML cells

1 reference

12 December 2020

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

1 reference

12 December 2020

Small molecule FLT3 tyrosine kinase inhibitors

1 reference

12 December 2020

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

12 December 2020

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation

1 reference

12 December 2020

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

12 December 2020

Preferential induction of apoptosis for primary human leukemic stem cells

1 reference

12 December 2020

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia

1 reference

12 December 2020

The role of tuberin in cellular differentiation: are B-Raf and MAPK involved?

1 reference

12 December 2020

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

1 reference

12 December 2020

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

12 December 2020

Imatinib: paradigm or anomaly?

1 reference

12 December 2020

Antileukemic activity of rapamycin in acute myeloid leukemia.

1 reference

12 December 2020

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

1 reference

12 December 2020

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

1 reference

12 December 2020

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

1 reference

12 December 2020

The molecular basis of leukemia

1 reference

12 December 2020

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

1 reference

12 December 2020

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

1 reference

12 December 2020

10.1007/S11864-007-0043-Z

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18097642